Exp Ther Med:白介素-33基因的单核苷酸多态性和单倍型与中国人群过敏性鼻炎的风险有关

2020-10-25 AlexYang MedSci原创

过敏性鼻炎(AR)是一种常见的上呼吸道疾病,且归因于多种风险因素,如环境暴露和遗传易感性。临床上常见哮喘和AR并存,表明这些疾病之间存在共同的遗传风险因素和生物学机制。

过敏性鼻炎(AR)是一种常见的上呼吸道疾病,且归因于多种风险因素,如环境暴露和遗传易感性。临床上常见哮喘和AR并存,表明这些疾病之间存在共同的遗传风险因素和生物学机制。

全基因组关联研究和和功能研究表明,白细胞介素(IL)-33是驱动哮喘易感性和发病机制的重要因素。尽管之前的研究已经报道了该基因与AR假定的关联,但仍然缺乏IL-33的基因变异与疾病关联的证据。最近,有研究人为了调查IL-33基因的变异是否与AR的遗传风险有关,他们在湖北省汉族居民中招募了769名AR患者和769名年龄、性别匹配的健康对照者,并对对IL-33基因的14个单核苷酸多态性(SNPs)与AR风险的关联性进行了研究。结果表明,5个位于IL-33的5'-侧翼区域的SNPs处于中度连锁不平衡状态,且与AR风险表现出显著的关联,这些关联还得到了基因型和单倍型分析的支持。值得注意的是,之前已有报道称该5个IL-33 SNPs中的3个SNPs与哮喘关联,且本研究中也发现它们的等位基因与AR风险增加有关。

IL-33 SNPs单倍型与过敏性鼻炎风险相关性分析

最后,研究人员指出,他们的结果表明了IL-33基因的某些变异代表着AR可能的风险,并揭示了AR与哮喘之间存在共同的遗传基础。

原始出处:

He Ran , Hua Xiao , Xing Zhou et al. Single-nucleotide polymorphisms and haplotypes in the interleukin-33 gene are associated with a risk of allergic rhinitis in the Chinese population. Exp Ther Med. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2021-04-22 xsm918
  2. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2020-10-27 xzw120
  7. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2020-10-25 sinze

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1945654, encodeId=634c1945654c9, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu Apr 22 08:00:01 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047323, encodeId=9ba3204e32363, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Dec 12 04:00:01 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372147, encodeId=3a6313e2147e7, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471753, encodeId=a83514e1753d2, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610767, encodeId=00a91610e6761, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629295, encodeId=ee7e162929500, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Tue Oct 27 06:00:01 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894359, encodeId=9e7e894359f8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/0G2KQrJ4107mFibibIPvibGXUfBtcINMCMKUo6Ju0Eha3sOLZJRDgDGu4ALqpvYc6V6yYgjPXFGFz6XnxCSkiawbBQ/132, createdBy=7b375251607, createdName=sinze, createdTime=Sun Oct 25 16:59:13 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894324, encodeId=2e2189432420, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:16:15 CST 2020, time=2020-10-25, status=1, ipAttribution=)]
    2020-10-25 ms3000000449926787

    学习了!

    0

相关资讯

Prostate Cancer P D:DNMT3B单核苷酸多态性和DNMT3B Mrna表达与前列腺癌死亡率相关

DNA甲基化转移酶3B(DNMT3B)的生殖系变异可能影响DNMT3B的酶活性,反过来,也可能通过改变DNA甲基化来影响癌症的恶化。最近,有研究人员在2个意大利前列腺癌群体(n=157和182)和2个美国前列腺癌群体(n=214和298)中进行了案例-对照研究。研究人员在NTAT群体中利用线性回归评估了选择的3个DNMT3B变异与全部DNA甲基化之间的相关性;在所有群体中利用Cox比例风险回归评估

Ann Rheum Dis:IL1RN基因变异可以预测膝骨关节炎的影像学严重性和疾病风险

携带IL1RN TTG单倍体与更严重的rOA、偶发性OA风险升高和RA炎症证据升高相关。

Eur Arch Otorhinolaryngol:过敏性鼻炎中IL-13和CD14基因单核苷酸多态性分析

最近,有研究人员进行了元分析,目的是研究白介素-13(IL-13)和分化群14(CD14)基因的单核苷酸多态性情况和过敏性鼻炎(AR)的风险情况。研究人员筛选了在7个数据库中的数据,包括了Pubmed、Medline、Web of Science、Embase、China Biology Medicine disc、 Wanfang和中国学术期刊网络出版数据库。研究人员利用让步比(ORs)和95%

JCLA:抵抗素基因单核苷酸多态性与类风湿关节炎的相关性研究

最近的证据表明,抵抗素与类风湿关节炎(RA)的发生发展有关。本研究旨在分析抵抗素基因单核苷酸多态性(SNPs)与RA易感性的关系。 研究人员采用TaqMan SNP基因分型分析方法,对278例RA患者和276例正常对照组的3个抗性蛋白SNP (rs1862513, rs3745368, rs3745367)进行分析。结果显示,RA患者与正常对照组的等位基因分布及三种snp基因型频率无显著性差

Ocul Immunol Inflamm:IL23R-IL12RB2的单核苷酸多态性在Behcet葡萄膜炎患者中非常普遍并具有人群差异

以色列Petach Tikva的拉宾医疗中心眼科的Kramer M近日在Ocul Immunol Inflamm发表了一项工作,他们检测了Behcet葡萄膜炎患者体内IL-10、IL23R-IL12RB2基因单核苷酸多态性的发生频率。

Sci Rep:TLR10和NFKBIA导致髋关节骨关节炎风险:基于中国汉族人群的系统评估

这项研究首次发现了来自NFKBIA与HOA的重要关联信号,并且还证实了TLR10会导致患HOA风险。